ISRCTN14404480 https://doi.org/10.1186/ISRCTN14404480

An evaluation of Motivational (MI) plus Cognitive Therapy (CBT) for Schizophrenia and Substance Misuse

Submission date
29/08/2003

Recruitment status
No longer recruiting

Registration date
01/09/2003

Overall study status
Completed

Last Edited
03/08/2009

Condition category
Mental and Behavioural Disorders

[X] Prospectively registered
[ ] Protocol
[ ] Statistical analysis plan
[X] Results
[ ] Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Christine Barrowclough

Contact details
Academic Division of Clinical Psychology
University of Manchester
School of Psychiatry and Behavioural Sciences
Education and Research Centre
Wythenshawe Hospital
Wythenshawe
Manchester
United Kingdom
M23 9LT
+44 (0)161 291 5881
christine.barrowclough@man.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
G0200471

Study information

Scientific Title

Acronym
Motivational Interventions for Drug and Alcohol Use in Schizophrenia (MIDAS)

Study objectives
The aim of the study is to evaluate the benefits of the adjunct of a psychological treatment over standard available care for patients with schizophrenia and a co-morbid drug or alcohol problem.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Not specified

Study type(s)
Treatment

Participant information sheet

Health condition(s) or problem(s) studied
Mental and behavioural disorder

Interventions
The experimental treatment (MI plus CBT) will consist of motivational interviewing to increase motivation to reduce substance use; CBT for help with both substance use reduction and symptom management; and relapse prevention strategies. Patients randomised to receive MI plus CBT will be offered up to 26 sessions over 12 months with treatment being located at home or clinic according to the patient's choice. The MI plus CBT treatment will be in addition to standard psychiatric care. The control group will receive standard psychiatric care alone.

Intervention Type
Other

Phase
Not Specified

Primary outcome measure
Either readmission to hospital for reason related to psychosis or death from any cause/not admitted to hospital in the 12 month post-treatment period.

Secondary outcome measures
Added as of 6 February 2007: Measures of symtomatology, relapses, substance misuse and health economic analyses.

Overall study start date
03/10/2004

Completion date
02/05/2009

Eligibility

Key inclusion criteria
1. Diagnostic and Statistical Manual of Mental Disorders, Fourth edition (DSM IV) diagnostic criteria for schizophrenia, schizophreniform or schizoaffective disorder
2. Recorded contact and treatment from mental health services at the point of recruitment
3. Prescribed anti-psychotic medication
4. Alcohol use exceeding 28 units for males, 21 units for females on at least half the weeks in the previous 3 months
5. DSM IV diagnosis of drug and/or alcohol dependence or abuse
6. No significant history of organic factors implicated in the aetiology of psychotic symptoms
7. English speaking
8. Informed patient consent
9. Having a fixed abode

Participant type(s)
Patient

Age group
Not Specified

Sex
Not Specified

Target number of participants
400

Key exclusion criteria
See inclusion criteria

Date of first enrolment
03/10/2004

Date of final enrolment
02/05/2009

Locations

Countries of recruitment
England

United Kingdom

Study participating centre
Academic Division of Clinical Psychology
Manchester
United Kingdom
M23 9LT

Sponsor information

Organisation
University of Manchester (UK)

Sponsor details
Oxford Road
Manchester
England
United Kingdom
M13 9PL
+44 (0)161 306 6000

Sponsor type
University/education

Website
http://www.manchester.ac.uk/

ROR
https://ror.org/027m9bs27

Funder(s)

Funder type
Research council

Funder Name
Medical Research Council (MRC) (UK)

Alternative Name(s)
Medical Research Council (United Kingdom), UK Medical Research Council, MRC

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location
United Kingdom

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/10/2009		Yes	No